重庆医学2024，Vol.53Issue(13)：2011-2015,5.DOI:10.3969/j.issn.1671-8348.2024.13.016
奥希替尼联合阿司匹林对晚期肺腺癌EGFR突变患者生存期的影响
Effect of osimertinib combined with aspirin on survival period in advanced lung adenocarcinoma patients with EGFR mutation
摘要
Abstract
Objective To investigate the effect of osimertinib combined with aspirin on the survival pe-riod of the advanced lung adenocarcinoma patients with epidermal growth factor receptor(EGFR)mutation.Methods Sixty lung adenocarcinoma patients with EGFR mutation in advanced non-small cell lung cancer(NSCLC)first diagnosed in Banan District Second People's Hospital of from August 2020 to October 2021 were selected as the study subjects and divided into the observation group and control group by the random number table method,30 cases in each group.The observation group adopted osimertinib combined with aspi-rin,and the control used osimertinib merely.The overall response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and the adverse reactions occurrence were compared between the two groups.Results ORR and DCR after 3,6,12 months medication in the observation group were higher than those in the control group,but the differences were not statistically significant(P＞0.05).Compared with the control group,PFS and OS in the observation group were longer,and the differences were statistically significant[14.9(11.8,17.2)m vs.10.5(8.9,12.5)m;24.1(19.5,27.4)m vs.18.1(16.1,21.1)m,P＜0.05].In addition,PFS and OS in male and female patients with brain metastasis,EGER19 and 21 ex-on mutation in the observation group were longer than those in the control group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in overall and≥Ⅲ degree adverse reactions between the two groups(P＞0.05).Conclusion Osimertinib combined with aspirin could prolong PFS and OS of the advanced lung adenocarcinoma patients with EGFR mutation without increasing the risk of adverse reactions.关键词
非小细胞肺癌/肺腺癌/表皮生长因子受体/酪氨酸激酶抑制剂/奥希替尼/阿司匹林/生存期Key words
non-small cell lung cancer/lung adenocarcinoma/epidermal growth factor receptor/tyrosine kinase inhibitors/osimertinib/aspirin/survival period分类
医药卫生引用本文复制引用
罗燕,姚岚,包中会,蒋义,倪燕侠,黄琴,李少林,任洪波,黄碧有..奥希替尼联合阿司匹林对晚期肺腺癌EGFR突变患者生存期的影响[J].重庆医学,2024,53(13):2011-2015,5.基金项目
原发性肺癌精准防治关键技术集成创新与应用课题(2019ZX002). （2019ZX002）
